MetLife Investment Management’s Kura Oncology KURA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $547K | Buy |
49,862
+11,051
| +28% | +$104K | ﹤0.01% | 1863 |
|
|
2026
Q1 | $316K | Sell |
38,811
-5,814
| -13% | -$49.9K | ﹤0.01% | 1975 |
|
|
2025
Q4 | $464K | Sell |
44,625
-744
| -2% | -$7.81K | ﹤0.01% | 1824 |
|
|
2025
Q3 | $402K | Buy |
45,369
+417
| +0.9% | +$2.97K | ﹤0.01% | 1913 |
|
|
2025
Q2 | $259K | Buy |
44,952
+3,970
| +10% | +$24.3K | ﹤0.01% | 2043 |
|
|
2025
Q1 | $270K | Sell |
40,982
-3,846
| -9% | -$30K | ﹤0.01% | 2034 |
|
|
2024
Q4 | $390K | Buy |
44,828
+2,776
| +7% | +$39.9K | ﹤0.01% | 1930 |
|
|
2024
Q3 | $822K | Hold |
42,052
| – | – | ﹤0.01% | 1501 |
|
|
2024
Q2 | $866K | Buy |
42,052
+4,720
| +13% | +$97K | 0.01% | 1421 |
|
|
2024
Q1 | $796K | Hold |
37,332
| – | – | 0.01% | 1426 |
|
|
2023
Q4 | $537K | Hold |
37,332
| – | – | ﹤0.01% | 1645 |
|
|
2023
Q3 | $340K | Buy |
37,332
+1,436
| +4% | +$14.6K | ﹤0.01% | 1862 |
|
|
2023
Q2 | $380K | Hold |
35,896
| – | – | ﹤0.01% | 1880 |
|
|
2023
Q1 | $439K | Hold |
35,896
| – | – | ﹤0.01% | 1722 |
|
|
2022
Q4 | $445K | Buy |
35,896
+946
| +3% | +$13.8K | ﹤0.01% | 1709 |
|
|
2022
Q3 | $477K | Hold |
34,950
| – | – | ﹤0.01% | 1672 |
|
|
2022
Q2 | $641K | Hold |
34,950
| – | – | 0.01% | 1492 |
|
|
2022
Q1 | $562K | Buy |
34,950
+11,227
| +47% | +$162K | ﹤0.01% | 1700 |
|
|
2021
Q4 | $332K | Hold |
23,723
| – | – | ﹤0.01% | 1746 |
|
|
2021
Q3 | $444K | Hold |
23,723
| – | – | ﹤0.01% | 1584 |
|
|
2021
Q2 | $495K | Hold |
23,723
| – | – | ﹤0.01% | 1573 |
|
|
2021
Q1 | $671K | Sell |
23,723
-3,516
| -13% | -$111K | 0.01% | 1361 |
|
|
2020
Q4 | $890K | Buy |
27,239
+3,131
| +13% | +$110K | 0.01% | 1191 |
|
|
2020
Q3 | $739K | Hold |
24,108
| – | – | 0.01% | 1178 |
|
|
2020
Q2 | $393K | Buy |
24,108
+10,456
| +77% | +$151K | ﹤0.01% | 1512 |
|
|
2020
Q1 | $136K | Hold |
13,652
| – | – | ﹤0.01% | 1904 |
|
|
2019
Q4 | $188K | Hold |
13,652
| – | – | ﹤0.01% | 2011 |
|
|
2019
Q3 | $207K | Hold |
13,652
| – | – | ﹤0.01% | 1928 |
|
|
2019
Q2 | $269K | Sell |
13,652
-27,304
| -67% | -$453K | ﹤0.01% | 1859 |
|
|
2019
Q1 | $679K | Buy |
40,956
+27,304
| +200% | +$421K | ﹤0.01% | 1891 |
|
|
2018
Q4 | $192K | Hold |
13,652
| – | – | ﹤0.01% | 1932 |
|
|
2018
Q3 | $239K | Buy |
13,652
+3,550
| +35% | +$68.1K | ﹤0.01% | 1985 |
|
|
2018
Q2 | $184K | Hold |
10,102
| – | – | ﹤0.01% | 1957 |
|
|
2018
Q1 | $189K | Hold |
10,102
| – | – | ﹤0.01% | 1919 |
|
|
2017
Q4 | $155K | Buy |
+10,102
| New | +$149K | ﹤0.01% | 2051 |
|
Other funds holding KURA
SCM
ACM
MetLife Investment Management's KURA Position: Q2 2026 in Review
MetLife Investment Management increased its Kura Oncology (KURA) stake by 28% in Q2 2026, buying an estimated $104K and bringing the position to 49,862 shares worth $547K. The position accounts for ﹤0.01% of the portfolio, ranked #1863.
MetLife Investment Management first reported a position in KURA in Q4 2017 and has held it in 35 quarters since. The position peaked at $890K in Q4 2020. 221 funds tracked by Wall St. Rank hold KURA as of Q2 2026.
- MetLife Investment Management held 49,862 shares of Kura Oncology worth $547K as of Q2 2026.
- MetLife Investment Management bought 11,051 Kura Oncology shares in Q2 2026, an estimated $104K.
- Kura Oncology made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1863 holding.
- MetLife Investment Management first reported a position in Kura Oncology in Q4 2017 and has held it in 35 quarters since.
- MetLife Investment Management's Kura Oncology position peaked at $890K in Q4 2020.
- 221 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.